| Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2 … S Cirak, V Arechavala-Gomeza, M Guglieri, L Feng, S Torelli, K Anthony, ... The Lancet 378 (9791), 595-605, 2011 | 1154 | 2011 |
| Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials K Anthony, S Cirak, S Torelli, G Tasca, L Feng, V Arechavala-Gomeza, ... Brain 134 (12), 3547-3559, 2011 | 162 | 2011 |
| Restoration of the dystrophin-associated glycoprotein complex after exon skipping therapy in Duchenne muscular dystrophy S Cirak, L Feng, K Anthony, V Arechavala-Gomeza, S Torelli, C Sewry, ... Molecular Therapy 20 (2), 462-467, 2012 | 148 | 2012 |
| A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice H Zhou, N Janghra, C Mitrpant, RL Dickinson, K Anthony, L Price, ... Human gene therapy 24 (3), 331-342, 2013 | 130 | 2013 |
| Dystrophin quantification: Biological and translational research implications K Anthony, V Arechavala-Gomeza, LE Taylor, A Vulin, Y Kaminoh, ... Neurology 83 (22), 2062-2069, 2014 | 126 | 2014 |
| Dystrophin Dp71 and the neuropathophysiology of Duchenne muscular dystrophy M Naidoo, K Anthony Molecular Neurobiology 57 (3), 1748-1767, 2020 | 105 | 2020 |
| Aberrant RNA processing events in neurological disorders K Anthony, JM Gallo Brain research 1338, 67-77, 2010 | 93 | 2010 |
| Antisense oligonucleotide-mediated exon skipping for Duchenne muscular dystrophy: progress and challenges V Arechavala-Gomeza, K Anthony, J Morgan, F Muntoni Current gene therapy 12 (3), 152-160, 2012 | 92 | 2012 |
| Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping K Anthony, V Arechavala-Gomeza, V Ricotti, S Torelli, L Feng, N Janghra, ... JAMA neurology 71 (1), 32-40, 2014 | 88 | 2014 |
| Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping K Anthony, V Arechavala-Gomeza, V Ricotti, S Torelli, L Feng, N Janghra, ... JAMA neurology 71 (1), 32-40, 2014 | 88 | 2014 |
| Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans- splicing T Rodriguez-Martin, K Anthony, MA Garcia-Blanco, SG Mansfield, ... Human molecular genetics 18 (17), 3266-3273, 2009 | 60 | 2009 |
| Exon skipping quantification by quantitative reverse-transcription polymerase chain reaction in Duchenne muscular dystrophy patients treated with the antisense oligomer eteplirsen K Anthony, L Feng, V Arechavala-Gomeza, M Guglieri, V Straub, ... Human Gene Therapy, Part B: Methods 23 (5), 336-345, 2012 | 49 | 2012 |
| RNA-based therapeutics for neurological diseases K Anthony RNA biology 19 (1), 176-190, 2022 | 37 | 2022 |
| The Duchenne muscular dystrophy gene and cancer L Jones, M Naidoo, LR Machado, K Anthony Cellular Oncology 44, 19-32, 2021 | 33 | 2021 |
| A survey of machine learning approaches applied to gene expression analysis for cancer prediction M Khalsan, LR Machado, ES Al-Shamery, S Ajit, K Anthony, M Mu, ... IEEE Access 10, 27522-27534, 2022 | 32 | 2022 |
| Expression, localization and tau exon 10 splicing activity of the brain RNA-binding protein TNRC4 JP Chapple, K Anthony, TR Martin, A Dev, TA Cooper, JM Gallo Human molecular genetics 16 (22), 2760-2769, 2007 | 23 | 2007 |
| A multicenter comparison of quantification methods for antisense oligonucleotide-induced DMD exon 51 skipping in Duchenne muscular dystrophy cell cultures M Hiller, MS Falzarano, I Garcia-Jimenez, V Sardone, RC Verheul, ... PLoS One 13 (10), e0204485, 2018 | 19 | 2018 |
| Tau mRNA is present in axonal RNA granules and is associated with elongation factor 1A T Malmqvist, K Anthony, JM Gallo Brain research 1584, 22-27, 2014 | 18 | 2014 |
| T cell responses to dystrophin in a natural history study of Duchenne muscular dystrophy K Anthony, P Ala, F Catapano, J Meng, J Domingos, M Perry, V Ricotti, ... Human Gene Therapy 34 (9-10), 439-448, 2023 | 6 | 2023 |
| Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma M Naidoo, L Jones, B Conboy, W Hamarneh, D D’Souza, K Anthony, ... Scientific reports 12 (1), 3200, 2022 | 6 | 2022 |
